Diabetes is the fifth cause of death in most developed countries.And despite all the technological innovations of recent years, still only 6.5 percent of people living with this pathology in Europe can achieve their therapeutic objectives.
On the occasion of the XI International Congress on Advanced Technologies and Diabetes Treatments (ATTD) that has been held in Vienna (Austria), Roche Diabetes Care has insisted on the importance of management solutions for diabetes.
"Diabetes is the epidemic of the 21st century and every day patients are left to their fate with their treatment," explained Jörg Hölzing, Global Strategy and Marketing Director of Roche Diabetes Care.
Given the high incidence of patients who still fail to achieve their therapeutic objectives "the solution requires a combination of different approaches that implies fundamental changes in the way in which care is provided," he added.
The solutions are supported by an open digital ecosystem that responds to personalized needs for the benefit of patients, professionals and managers.
“We are convinced that if we focus on the ecosystem we get solutions for diabetes.The combination of therapy and technology to address clinical inertia is necessary, ”Hölzing continued."This includes the adoption of a structured and personalized therapeutic approach in which the study‘ PDM Provalue ’has proven effective, as well as supporting the complex decisions facing doctors and patients," he added.
The objective of the ‘PDM-Pro Value’ study was to demonstrate the benefits of the comprehensive approach to diabetes against the usually established approach.
The essay was carried out with more than 900 patients treated in Germany.During the presentation, the speakers have ensured that the results underline “the efficiency and effectiveness of the integrated and structured concept” of personalized diabetes management (IPDM): in the controls of the glycosilated hemoglobin test (HBA1C), The average glucose level was significantly reduced by 0.5 percent in the group that followed the program 12 months after starting the study.
"The personalized management of diabetes is a systematic process focused on medical-patient interaction," said Bernhard Kulzer, a professor at the Mergentheim Diabetes Center, at Bad Mergentheim, Germany.
“The monitoring of the treatment results thanks to the new technologies incorporated into the therapy allow adjustments quickly.These adjustments can be both pharmacological and non -pharmacological, ”said the expert.Another conclusion has been the best adhesion to treatment.
